Current Research Results
BioNTech recently presented promising results from its cancer research at the AACR Annual Meeting 2025, which have once again strengthened investor interest and confidence. These developments could have positive effects on the stock price and are of great significance for investors.
The company presented preclinical data on its antibody candidate BNT314/GEN1059, which is being developed in collaboration with Genmab. This candidate targets EpCAMx4-1BB and has been tested in combination with a PD-1 blockade. The results showed anti-tumor activity, delayed tumor growth, and delayed tumor spread, as well as prolonged survival compared to single treatments.
Oncology Pipeline
BioNTech has built a comprehensive oncology pipeline that includes over 20 active Phase 2 and Phase 3 studies in various solid tumors. The company expects numerous data updates in 2025 and 2026 that are meant to support its strategy of becoming a diversified multi-product company in the field of oncology.
Market Development and Investor Interest
Despite the encouraging research results, BioNTech’s stock on NASDAQ has slightly declined after initial gains. On Thursday, the stock gained 4.97%, while on Friday it temporarily fell by 2.03%. Deutsche Bank has reaffirmed a ‘Buy’ rating for BioNTech, which could further strengthen investor interest.
Outlook
The presentation of the promising research results at AACR 2025 and the reaffirmation of the ‘Buy’ rating by Deutsche Bank could have positive long-term effects on BioNTech’s stock price. Investors are watching the future developments and data updates from the company’s oncology pipeline with great interest, as these are crucial for BioNTech’s future growth strategy.